论文部分内容阅读
蛋白质的乙酰化修饰是转录后调控的重要机制之一。近年大量研究证实,蛋白乙酰化修饰异常与多种肿瘤组织的发生密切相关。随着对蛋白乙酰化研究的深入及组蛋白去乙酰化酶抑制剂(HDACIs)作为新型抗肿瘤药物进入临床的评估,有学者开始研究子宫内膜癌发生与相关基因蛋白修饰的关系,HDACIs的抗肿瘤治疗方案有望成为治疗子宫内膜癌的新方法。本文就组蛋白的乙酰化修饰与子宫内膜癌的发生、发展及HDACIs用于子宫内膜癌治疗方面的研究做一综述。
Acetylation of proteins is one of the important mechanisms of post-transcriptional regulation. In recent years, a large number of studies have confirmed that protein acetylation abnormalities and a variety of tumor tissues are closely related. With the deepening of the research on protein acetylation and the clinical evaluation of histone deacetylase inhibitors (HDACIs) as novel antitumor drugs, some scholars began to study the relationship between the occurrence of endometrial cancer and the modification of related gene proteins. HDACIs Anti-cancer treatment program is expected to become a new method of treatment of endometrial cancer. This article reviews the histone acetylation modification and the occurrence and development of endometrial carcinoma and the research of HDACIs in the treatment of endometrial carcinoma.